Management of acquired, immune thrombocytopenic purpura (iTTP): beyond the acute phase.

ABSTRACT: Modern therapy for acute TTP has resulted in a dramatic improvement in outcomes, with the combination of plasma exchange, immunosuppression, and caplacizumab being associated with >90% survival rates following an acute episode. TTP is no longer associated with just the acute episode, but requires long-term follow-up. There remains significant morbidity associated with acute TTP, and many patients suffer marked neuropsychological sequelae, including impairment in cognitive functioning, affective disorders, and reduction in health-related quality of life measures. The focus of management beyond the acute phase centres on relapse prevention, via careful monitoring of patients and the use of either ad hoc or regular immunosuppressive therapies. The main therapy used is rituximab, but de

SUBMITTER: Westwood JP 

PROVIDER: S-EPMC9340390 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature